Adjunctive use of statins in pandemic politics


Jamshid Tabeshpour and Mehri Bemani Naeini*

Since antiviral agents and vaccines are unavailable in all countries, we should determine whether other available agents could yield clinical benefits for treatment and prophylaxis of pandemic disease. Drug repurposing, an effective drug discovery strategy from existing drugs, shortens the time and diminish the cost compared to de novo drug discovery. An achievable but effective treatment is needed, particularly by FDA-approved medications. SARS-CoV-2-induced disease is associated with a boosted cardiovascular disease and induces proinflammatory cytokines. Statins show immunomodulatory effects, and could be useful in the control of life-threatening infections and proinflammatory cytokine dysregulation which confirmed by reduced rates of hospitalization and death in patients. Statins are globally distributed and cheap. They might be one of the most valuable agents that could alter the course of this pandemic. We have inadequate supplies of antiviral agents, and antiviral resistance might limit their usefulness against viruses. Millions of people will have to wait many months or more for availability of supplies of pandemic vaccines. Also, obtaining sufficient supplies of pandemic vaccines with antigen-sparing technologies to meet global demand may be inaccessible. Research in the operative vaccines and antiviral drugs development, has been time consuming. Statins effectiveness to alleviate the inducing influence of SARS-CoV-2 on the immune system merits assessment, such we certainly do require to consider randomized trial evidences in prophylaxis and treatment.

Share this article

Awards Nomination

Select your language of interest to view the total content in your interested language

Indexed In
  • Index Copernicus
  • Sherpa Romeo
  • Open J Gate
  • Academic Keys
  • CiteFactor
  • Electronic Journals Library
  • OCLC- WorldCat
  • Academic Resource Index